Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nano-hydroxyapatite (nHAp) is a synthetic, biocompatible, and bioactive material that chemically and structurally mimics the natural mineral component of human bone and tooth enamel. In dentistry, it is primarily utilized for the remineralization of enamel and the management of dentin hypersensitivity, including cases associated with Molar Incisor Hypomineralization (MIH). The mechanism of action involves the deposition of nanoparticles into open dentinal tubules, effectively occluding them and reducing the transmission of painful stimuli to the dental pulp. Furthermore, nHAp acts as a reservoir for calcium and phosphate ions, promoting the formation of a new apatite layer on the tooth surface, which restores structural integrity and protects against acid erosion. It is often formulated as a varnish, gel, or paste for topical application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nanohydroxyapatite (Cairo University).